

Luis-Emilio GarcÃ-a-PÃ©rez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9019891/publications.pdf>

Version: 2024-02-01

16
papers

970
citations

933264

10
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

1593
citing authors

#	ARTICLE	IF	CITATIONS
1	Glycaemic variability in patients with type 2 diabetes mellitus treated with dulaglutide, with and without concomitant insulin: Post hoc analyses of randomized clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 631-640.	2.2	1
2	Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes. <i>Quality of Life Research</i> , 2021, 30, 2033-2043.	1.5	7
3	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics. <i>Diabetes Therapy</i> , 2021, 12, 1929-1946.	1.2	5
4	Assessing patient PREFERENCE between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 355-364.	2.2	31
5	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes. <i>Diabetes Therapy</i> , 2020, 11, 2383-2399.	1.2	5
6	Cover Image, Volume 22, Issue 3. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, .	2.2	0
7	Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2570-2575.	2.2	11
8	Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1299-1304.	2.2	36
9	<p></p>Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes</p>. <i>Patient Preference and Adherence</i> , 2019, Volume 13, 561-576.	0.8	28
10	Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK. <i>Drugs in R and D</i> , 2019, 19, 213-225.	1.1	10
11	Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 370-381.	5.5	185
12	Effect of once weekly dulaglutide by baseline beta cell function in people with type 2 diabetes in the AWARD programme. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2023-2028.	2.2	20
13	Effect of once-weekly dulaglutide on glycated haemoglobin (<sc>HbA1c</sc>) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline <sc>HbA1c</sc>. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 409-418.	2.2	56
14	Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1573-1581.	0.8	44
15	Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers. <i>Postgraduate Medicine</i> , 2016, 128, 810-821.	0.9	17
16	Adherence to Therapies in Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2013, 4, 175-194.	1.2	514